Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)
No Thumbnail Available
Date
2021-08-11
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Reliable serum biomarkers are of immense need for diagnostic purposes of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a disabling and complex disease for which diagnosis is mainly based on clinical symptoms. The aim of this study was to evaluate a possible diagnostic potential of activin B by directly comparing 134 cases of ME/CFS with 54 healthy controls. Analyses of human activin B level in plasma samples were performed using a validated human activin B ELISA assay. The results of the study show that activin B levels did not differ statistically significantly between ME/CFS patients and healthy controls (p = 0.6511). No gender or age‐related differences in activin B levels were observed in the ME/CFS group and healthy controls. The level of activin B tended to decrease with increasing visual analogue scale score (r = −0.2004; p = 0.5085) nevertheless the results obtained so far does not support the clinical utility of activin B as a bi-omarker for ME/CFS.
Description
Funding Information: This research was funded by the Latvian Science Council?s Fundamental and Applied Research project, grant number LZP?2019/1?0380. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Keywords
Human activin B, ME/CFS, Visual analogue scale, 3.1 Basic medicine, 1.1. Scientific article indexed in Web of Science and/or Scopus database, Biochemistry, Molecular Biology, SDG 3 - Good Health and Well-being
Citation
Gravelsina, S, Nora‐krukle, Z, Vilmane, A, Svirskis, S, Vecvagare, K, Krūmiņa, A & Murovska, M 2021, 'Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)', Biomolecules, vol. 11, no. 8, 1189. https://doi.org/10.3390/biom11081189